0001549595-24-000020.txt : 20240215
0001549595-24-000020.hdr.sgml : 20240215
20240215072328
ACCESSION NUMBER: 0001549595-24-000020
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240213
FILED AS OF DATE: 20240215
DATE AS OF CHANGE: 20240215
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: van Houte Hans
CENTRAL INDEX KEY: 0001817217
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39398
FILM NUMBER: 24642060
MAIL ADDRESS:
STREET 1: C/O NURIX THERAPEUTICS, INC.
STREET 2: 1700 OWENS STREET, SUITE 205
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Nurix Therapeutics, Inc.
CENTRAL INDEX KEY: 0001549595
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 270838048
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1130
BUSINESS ADDRESS:
STREET 1: 1700 OWENS STREET, SUITE 205
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
BUSINESS PHONE: (415) 660-5320
MAIL ADDRESS:
STREET 1: 1700 OWENS STREET, SUITE 205
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
FORMER COMPANY:
FORMER CONFORMED NAME: Nurix, Inc.
DATE OF NAME CHANGE: 20120509
4
1
wk-form4_1707999800.xml
FORM 4
X0508
4
2024-02-13
0
0001549595
Nurix Therapeutics, Inc.
NRIX
0001817217
van Houte Hans
C/O NURIX THERAPEUTICS, INC.
1700 OWENS STREET, SUITE 205
SAN FRANCISCO
CA
94158
0
1
0
0
Chief Financial Officer
0
Employee Stock Option (right to buy)
8.72
2024-02-13
4
A
0
150000
0
A
2034-02-12
Common Stock
150000
150000
D
Restricted Stock Units
0
2024-02-13
4
A
0
45000
0
A
Common Stock
45000
45000
D
The stock option vests as to 1/36 of the total shares monthly beginning March 13, 2024, until the option is fully vested on February 13, 2027, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2024, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.
RSUs do not expire; they either vest or are canceled prior to the vest date.
/s/ Daniel Burbach, as Attorney-in-Fact for Hans van Houte
2024-02-15